Literature DB >> 11456355

Serum interleukin-6 and tumor necrosis factor-alpha concentrations in children with mycoplasma pneumonia.

C C Hsieh1, R B Tang, C H Tsai, W Chen.   

Abstract

A prospective study was performed to assess the relationship among interleukin-6, tumor necrosis factor-alpha, C-reactive protein serum concentrations, and the severity of mycoplasma pneumonia in 49 children. Mycoplasma pneumonia was diagnosed by chest film and anti-Mycoplasma pneumoniae IgM antibody test. Serum concentrations of interleukin-6 and tumor necrosis factor-alpha were measured by using enzyme-linked immunosorbent assays. Interleukin-6 serum levels in mycoplasma pneumonia patients with fever for more than 3 days (41.98 +/- 67.46 [SD] pg/mL) were significantly higher than those in patients with fever < or = 3 days (10.01 +/- 11.74 pg/mL, p < 0.05). Interleukin-6 serum levels in those patients whose chest films revealed patchy consolidations or pleural effusion (58.11 +/- 92.19 pg/mL) were significantly higher than those in patients whose chest films revealed peribronchial interstitial infiltration (15.94 +/- 20.81 pg/mL, p < 0.05). The mean levels of serum tumor necrosis factor-alpha were not statistically significant in the different duration of fever and chest film findings. These results suggest that interleukin-6 serum concentration, rather than tumor necrosis factor-alpha, may be a potential indicator of the severity and outcome of mycoplasma pneumonia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11456355

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  8 in total

1.  Reactive oxygen species mediate Jak2/Stat3 activation and IL-8 expression in pulmonary epithelial cells stimulated with lipid-associated membrane proteins from Mycoplasma pneumoniae.

Authors:  Sang Yong Choi; Joo Weon Lim; Takashi Shimizu; Koichi Kuwano; Jung Mogg Kim; Hyeyoung Kim
Journal:  Inflamm Res       Date:  2012-01-24       Impact factor: 4.575

Review 2.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

3.  The differential diagnostic values of cytokine levels in pleural effusions.

Authors:  Saadet Akarsu; A Nese Citak Kurt; Yasar Dogan; Erdal Yilmaz; Ahmet Godekmerdan; A Denizmen Aygun
Journal:  Mediators Inflamm       Date:  2005-02-24       Impact factor: 4.711

4.  High expression of HMGB1 in children with refractory Mycoplasma pneumoniae pneumonia.

Authors:  Ying Ding; Chu Chu; Yuqin Li; Gen Li; Xiaoli Lei; Weifang Zhou; Zhengrong Chen
Journal:  BMC Infect Dis       Date:  2018-08-29       Impact factor: 3.090

5.  Critical combination of initial markers for predicting refractory Mycoplasma pneumoniae pneumonia in children: a case control study.

Authors:  Young-Jin Choi; Ju-Hee Jeon; Jae-Won Oh
Journal:  Respir Res       Date:  2019-08-23

6.  Vaccination with Mycoplasma pneumoniae membrane lipoproteins induces IL-17A driven neutrophilia that mediates Vaccine-Enhanced Disease.

Authors:  Arlind B Mara; Tyler D Gavitt; Edan R Tulman; Jeremy M Miller; Wu He; Emily M Reinhardt; R Grace Ozyck; Meagan L Goodridge; Lawrence K Silbart; Steven M Szczepanek; Steven J Geary
Journal:  NPJ Vaccines       Date:  2022-07-29       Impact factor: 9.399

7.  The clinical significance of IL-6 s and IL-27 s in Bronchoalveolar lavage fluids from children with mycoplasma pneumoniae pneumonia.

Authors:  Jie Zhao; Yuyun Li; Wen Zhang
Journal:  BMC Infect Dis       Date:  2020-05-11       Impact factor: 3.090

8.  Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children.

Authors:  Akihiro Tamura; Kousaku Matsubara; Takayuki Tanaka; Hiroyuki Nigami; Kazuo Yura; Takashi Fukaya
Journal:  J Infect       Date:  2008-07-25       Impact factor: 6.072

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.